

REFERENCES – TOWN HALL 74 – 5-15-2022

CHINESE RECEPTOR BINDING DOMAIN PROTEIN SUBUNIT VACCINE DEMONSTRATES SAFETY AND EFFICACY IN A PLACEBO-CONTROLLED TRIAL.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2202261>

DOES THE WORLD STILL NEED NEW COVID-19 VACCINES?

<https://www.nejm.org/doi/full/10.1056/NEJMe2204695>

TWO 50 MICROGRAM DOSES OF THE MODERNA VACCINE WERE IMMUNOGENIC AND ESTIMATED TO BE 88% EFFECTIVE IN PREVENTING SARS-CoV-2 INFECTION IN CHILDREN 6 TO 11 YEARS OF AGE.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2203315>

TWO-YEARS LATER COVID-19 SURVIVORS HAVE LOWER HEALTH STATUS THAN THE GENERAL POPULATION.

[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(22\)00126-6/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00126-6/fulltext)

SARS-CoV-2 ANTIGEN CHALLENGE HISTORIES INFLUENCE THE SPEED AND MAGNITUDE OF ANTIBODY RESPONSES, FUNCTIONAL CROSS-VARIANT ANTIBODY REPERTOIRE COMPOSITION, AND LONGEVITY OF PROTECTION.

<https://www.science.org/doi/10.1126/sciimmunol.abp8328>

RECENT VACCINATION PROTECTS AGAINST SEVERE OMICRON SEQUELAE.

<https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac161/6575414?login=false>

SARS-CoV-2 VIREMIA IS ASSOCIATED WITH COVID-19 SEVERITY AND PREDICTS CLINICAL OUTCOMES.

<https://academic.oup.com/cid/article/74/9/1525/6347519>

FIRST HUMAN SARS-CoV-2 CHALLENGE STUDY CONDUCTED AND EVALUATED EARLY KINETICS OF INFECTION (PREPRINT, NOT YET PEER-REVIEWED).

<https://www.researchsquare.com/article/rs-1121993/v1>

**HOW TO PREVENT THE NEXT PANDEMIC, BY BILL GATES. PUBLISHED BY ALFRED KNOPF
MAY 03, 2022. ISBN 9780593534489**

<https://www.penguinrandomhouse.com/books/704751/how-to-prevent-the-next-pandemic-by-bill-gates/>